1H NMR based metabolomics of CSF and blood serum: A metabolic profile for a transgenic rat model of Huntington disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 11, 2011, Pages 1371-1379

  Verwaest, Kim A ^a   Vu, Trung N ^a   Laukens, Kris ^a   Clemens, Laura E ^a,b   Nguyen, Huu P ^a,b   Van Gasse, Bjorn ^a,c   Martins, José C ^a,c   Van Der Linden, Annemie ^a,c   Dommisse, Roger ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

1H NMR spectroscopy; CSF; Huntington disease; Metabolomics; Serum; Transgenic rat

Indexed keywords

GLUCOSE; GLUTAMIC ACID; GLUTAMINE; LACTIC ACID; N ACETYLASPARTIC ACID; SUCCINATE DEHYDROGENASE; SUCCINIC ACID;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASYMPTOMATIC DISEASE; CELL ENERGY; CEREBROSPINAL FLUID; CITRIC ACID CYCLE; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE UTILIZATION; HUNTINGTON CHOREA; METABOLIC DISORDER; METABOLOMICS; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SERUM; STOICHIOMETRY;

ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; FEMALE; HUNTINGTON DISEASE; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOMICS; PRINCIPAL COMPONENT ANALYSIS; RATS; RATS, TRANSGENIC;

RATTUS;

EID: 80052599009     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.08.001     Document Type: Article

References (52)

1. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
2. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., Beal M.F. Creatine increases survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 2001, 8:479-491.
3. Tabrizi S.J., Cleeter M.W.J., Xuereb J., Taanman J.-W., Cooper J.M., Schapira A.H.V. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45:25-32.
4. Jenkins B.G., Klivenyi P., Kustermann E., Andreassen O.A., Ferrante R.J., Rosen B.R., Beal M.F. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem. 2000, 74:2108-2119.
5. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
6. Bundy J.G., Davey M.P., Viant M.R. Environmental metabolomics: a critical review and future perspectives. Metabolomics 2009, 5:3-21.
7. Lindon J.C., Nicholson J.K., Holmes E. The Handbook of Metabonomics and Metabolomics 2007, Elsevier, Amsterdam.
8. Viant M.R., Lyeth B.G., Miller M.G., Berman R.F. An NMR metabolomic investigation of early metabolic disturbances following traumatic brain injury in a mammalian model. NMR Biomed. 2005, 18:507-516.
9. Petroff O.A.C., Yu R.K., Ogino T. High-resolution proton magnetic resonance analysis of human cerebrospinal fluid. J. Neurochem. 1986, 47:1270-1276.
10. Khandelwal P., Beyer C.E., Lin Q., Schechter L.E., Bach A.C. Studying rat brain neurochemistry using nanoprobe NMR spectroscopy: a metabonomics approach. Anal. Chem. 2004, 76:4123-4127.
11. Lindon J.C., Nicholson J.K., Everett J.R. NMR spectroscopy of biofluids. Annu. Rep. Spectrosc. 1999, 38:1-88.
12. 1H NMR spectroscopic data processing for high-throughput metabolic phenotyping studies and detection of insulin resistance related to type 2 diabetes. Anal. Chem. 2008, 80:7354-7362.
13. Lindon J.C., Holmes E., Nicholson J.K. Pattern recognition methods and applications in biomedical magnetic resonance. Prog. Nucl. Magn. Reson. Spectrosc. 2001, 39:1-40.
14. 1H NMR-based metabonomic techniques to distinguish between HIV-1 positive/AIDS patients on antiretroviral treatment and HIV-1 negative individuals. J. Pharm. Biomed. Anal. 2006, 41:1442-1446.
15. Constantinou M.A., Tsantili-Kakoulidou A., Andreadou I., Iliodromitis E.K., Kremastinos D.T., Mikros E. Application of NMR-based metabonomics in the investigation of myocardial ischemia-reperfusion, ischemic preconditioning and antioxidant intervention in rabbits. Eur. J. Pharm. Sci. 2007, 30:303-314.
16. 1H NMR spectroscopy studies of Huntington's disease - correlations with CAG repeat numbers. Neurology 1998, 50:1357-1365.
17. 1H MR spectroscopy. Korean J. Radiol. 2002, 3:180-188.
18. 1H NMR spectroscopy. Anal. Biochem. 2001, 291:17-26.
19. Bender A., Auer D.P., Merl T., Reilmann R., Saemann P., Yassouridis A., Bender J., Weindl A., Dose M., Gasser T., Klopstock T. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J. Neurol. 2005, 252:36-41.
20. Kasparová S., Sumbalová Z., Bystrickỳ P., Kucharská J., Liptaj T., Mlynárik V., Gvozdjáková A. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease. Neurochem. Int. 2006, 48:93-99.
21. Verbessem P., Lemiere J., Eijnde B.O., Swinnen S., Vanhees L., Van Leemputte M., Hespel P., Dom R. Creatine supplementation in Huntington's disease - a placebo-controlled pilot trial. Neurology 2003, 61:925-930.
22. 1H NMR spectroscopy. J. Neurosci. Res. 2001, 66:891-898.
23. Holmes E., Antti H. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst 2002, 127:1549-1557.
24. Alam T.M., Alam M.K. Chemometric analysis of NMR spectroscopy data: a review. Annu. Rep. Spectrosc. 2005, 54:41-80.
25. 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J. Pharm. Biomed. Anal. 2004, 36:841-849.
26. El-deredy W. Pattern recognition approaches in biomedical and clinical magnetic resonance spectroscopy: a review. NMR Biomed. 1997, 10:99-124.
27. 1H NMR spectroscopy. J. Proteome Res. 2006, 5:483-492.
28. von Hörsten S., Schmitt I., Nguyen H.P., Holzmann C., Schmidt T., Walther T., Bader M., Pabst R., Kobbe P., Krotova J., Stiller D., Kask A., Vaarmann A., Rathke-Hartlieb S., Schulz J.B., Grasshoff U., Bauer I., Vieira-Saecker A.M.M., Paul M., Jones L., Lindenberg K.S., Landwehrmeyer B., Bauer A., Li X.J., Riess O. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 2003, 12:617-624.
29. 1H NMR spectroscopy. NMR Biomed. 2007, 20:401-412.
30. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7105-7109.
31. 1H NMR spectroscopy. J. Neurochem. 2009, 100:1397-1406.
32. Sibson N.R., Dhankhar A., Mason G.F., Rothman D.L., Behar K.L., Shulman R.G. Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:316-321.
33. Conforti P., Ramos C., Apostol B.L., Simmons D.A., Nguyen H.P., Riess O., Thompson L.M., Zuccato C., Cattaneo E. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol. Cell. Neurosci. 2008, 39:1-7.
34. Khandelwal P., Beyer C.E., Lin Q., McGonigle P., Schechter L.E., Bach A.C. Nanoprobe NMR spectroscopy and in vivo microdialysis: new analytical methods to study brain neurochemistry. J. Neurosci. Methods 2004, 133:181-189.
35. Eriksson L., Johansson E., Antti H., Holmes E. Multi-and megavariate data analysis: finding and using regularities in metabonomics data. Metabolomics in Toxicity Assessment 2005, 263-335. Taylor & Francis Group, Boca Raton. D.G. Robertson, J. Lindon (Eds.).
36. Westerhuis J.A., Hoefsloot H.C.J., Smit S., Vis D.J., Smilde A.K., van Velzen E.J.J., van Duijnhoven J.P.M., van Dorsten F.A. Assessment of PLSDA cross validation. Metabolomics 2008, 4:81-89.
37. Cristianini N., Shawe-Taylor J. An Introduction to Support Vector Machines and Other Kernel-Based Learning Methods 2000, Cambridge University Press, Cambridge.
38. Nguyen H.P., Kobbe P., Rahne H., Wörpel T., Jäger B., Stephan M., Pabst R., Holzmann C., Riess O., Korr H., Kántor O., Petrasch-Parwez E., Wetzel R., Osmand A., von Hörsten S. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Hum. Mol. Genet. 2006, 15:3177-3194.
39. Hurlbert M.S., Zhou W., Wasmeier C., Kaddis F.G., Hutton J.C., Freed C.R. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 1999, 48:649-651.
40. Browne S.E., Beal M.F. The energetics of Huntington's disease. Neurochem. Res. 2004, 29:531-546.
41. Ciarmiello A., Cannella M., Lastoria S., Simonelli M., Frati L., Rubinsztein D.C., Squitieri F. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 2006, 47:215-222.
42. 1H NMR spectroscopy. Neurology 1993, 43:2689-2695.
43. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H.V. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39:385-389.
44. Mathews C.K., van Holde K.E., Ahern K.G. Carbohydrate Metabolism I: Anaerobic Processes in Generating Metabolic Energy, Biochemistry 2000, 446-482. Addison Wesley Longman, San Francisco.
45. Underwood B.R., Broadhurst D., Dunn W.B., Ellis D.I., Michell A.W., Vacher C., Mosedale D.E., Kell D.B., Barker R.A., Grainger D.J., Rubinsztein D.C. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006, 129:877-886.
46. Dautry C., Condé F., Brouillet E., Mittoux V., Beal M.F., Bloch G., Hantraye P. Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiol. Dis. 2006, 6:259-268.
47. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M.K., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41:646-653.
48. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H.V. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39:385-389.
49. Demougeot C., Marie C., Giroud M., Beley A. N-acetylaspartate: a literature review of animal research on brain ischaemia. J. Neurochem. 2004, 90:776-783.
50. Choi J.K., Dedeoglu A., Jenkins B.G. Application of MRS to mouse models of neurodegenerative illness. NMR Biomed. 2007, 20:216-237.
51. van Dellen A., Welch J., Dixon R.M., Cordery P., York D., Styles P., Blakemore C., Hannan A.J. N-acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport 2000, 11:3751-3757.
52. 1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res. 2007, 1168:67-71.